Short answer
Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on August 28, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). Spero authorized an at-the-market equity offering of up to $100 million through Jefferies.
Spero Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Spero authorized an at-the-market equity offering of up to $100 million through Jefferies
- Sales cannot begin until the $300 million universal shelf registration becomes effective
- Potential proceeds provide financing flexibility, but future share issuance would dilute existing shareholders
- Jefferies compensation up to 3.0% of gross proceeds, reducing net capital raised
Item 8.01 · Other Events
- Cantor ATM agreement terminated effective August 28, 2026
- $75 million equity issuance capacity eliminated under the Cantor Prospectus
- No termination penalties incurred, limiting immediate cash costs
- No shares sold through the facility during fiscal years 2025 or 2024
- Future common-stock sales through this ATM offering are no longer available
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spero Therapeutics Inc 8-K filings
Get the next SPRO 8-K as it lands
Follow SPRO for push alerts, or ask the research agent what this filing means.